In one paragraphArticle in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Beatriz L Pires-LimaLAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto 4169-007, Portugal.ORCID 0000-0003-1464-7254 Sara C Silva-ReisLAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto 4169-007, Portugal.ORCID 0000-0003-2024-0696 Xavier Cruz CorreiaLAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto 4169-007, Portugal.ORCID 0000-0002-1440-9873 Hugo F Costa-AlmeidaLAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto 4169-007, Portugal.ORCID 0000-0002-9034-2076 Vera M CostaUCIBIO, REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto 4050-313, Portugal.ORCID 0000-0002-0471-2756 Xerardo García-MeraDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela E-15782, Spain.ORCID 0000-0001-5218-6351 José BreaInnopharma Screening Platform. Biofarma Research Group. Centre of Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela E-15782, Spain.ORCID 0000-0002-5523-1979 María I LozaInnopharma Screening Platform. Biofarma Research Group. Centre of Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela E-15782, Spain.ORCID 0000-0003-4730-0863 Marialessandra ContinoDepartment of Pharmacy - Pharmaceutical Sciences, University of Bari "Aldo Moro", Via E. Orabona 4, Bari 70125, Italy.ORCID 0000-0002-0713-3151 Maria Grazia PerroneDepartment of Pharmacy - Pharmaceutical Sciences, University of Bari "Aldo Moro", Via E. Orabona 4, Bari 70125, Italy.ORCID 0000-0003-4195-5228 Giovanni GrazianoDepartment of Pharmacy - Pharmaceutical Sciences, University of Bari "Aldo Moro", Via E. Orabona 4, Bari 70125, Italy.ORCID 0000-0002-5575-3240 Nuno ValePerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Porto 4200-319, Portugal.ORCID 0000-0002-1283-1042 José E Rodríguez-BorgesLAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto 4169-007, Portugal.ORCID 0000-0002-9104-1670 Ivo E Sampaio-DiasLAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto 4169-007, Portugal.ORCID 0000-0002-9071-6197 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Parkinson's disease (PD) therapy remains limited by complications of the levodopa regimen, highlighting the need for novel therapeutic strategies to modulate dopaminergic signaling. Melanostatin (MIF-1) has attracted attention as a privileged scaffold for dopamine D
Indexed as
MSH Release-Inhibiting HormoneNeuroprotective AgentsNiacinReceptors, Dopamine D2AnimalsCell Line, TumorHumansStructure-Activity RelationshipMSH Release-Inhibiting HormoneNeuroprotective AgentsNiacinReceptors, Dopamine D2
Identifiers
PMID42312436
PMCPMC13370884
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390